Shots:

• Biolojic to receive ~$121M including development and commercialization milestones and a promissory note that may be convertible into Biolojic equity in future
• Additionally- Biolojic is eligible to receive royalties on sales of therapies that emerges during the collaboration
• The collaboration will leverage Biolojic's AI-based multibody platform to discover and develop a potential novel Ab-based therapy for diabetes

 ­ Ref: PRNewswire | Image: US News